A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in
patients with chronic schizophrenia that are not responding adequately to their current
antipsychotic medication (aripiprazole or risperidone). NW-3509A is given as an oral dose
range of 15 to 25 mg, BID in a 1:1 ratio.